
US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic …

The competitive hepatitis C market is to get another contender, with FDA approving MSD’s new combo treatment Zepatier (elbasvir and …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

